- 2015 Medical Marijuana Conference, all presentations
Original Date: July 11-12, 2015This discounted package includes all of the individual presentations from the conference.12.0 CEUs (4.75 general and 7.25 pharmacy) approved by OBNM - The Chemistry of Cannabis
Presenter: Kevin Spelman, PhD, MCPPOriginal Date: July 11, 2015
While THC is an interesting molecule there are many more active molecules in the plant beyond cannabinoids, including stilbenes, flavonoids and terpenes. We will review the cannabinoids, terpenes and the other lesser discussed constituents and their pharmacological role in Cannabis.
1.5 pharmacy CEUs approved by OBNM - Cannabis and Substance Dependence: From Gateway to Exit Drug
Presenter: Amanda Reiman, PhD, MSWOriginal Date: July 11, 2015
Traditionally, cannabis has been lumped in with other drugs of dependence and has been classified as a gateway drug to more harmful substances. Others claim that cannabis dependence does not exist at all. This issue is complicated by the fact that cannabis dependence might not present in a similar fashion to other substances of abuse. This session will review what is known about cannabis dependence and its function as a gateway drug. Then, this session will explore the modern day use of cannabis as an exit drug, helping people reduce or eliminate their use of more harmful substances. Recent research in this area will be discussed.
1.5 general CEUs approved by OBNM - Cannabis Policies: Changes in the US and Abroad
Presenter: Amanda Reiman, PhD, MSWOriginal Date: July 11, 2015
Cannabis prohibition has been in effect in most of the world for decades. However, starting in 1996 with the passage of Prop 215 in California, there has been a tidal wave of changes to cannabis regulations in the U.S. and across the globe. This session will focus on tracking those changes and the reasoning behind them, both nationally and internationally. This session will also focus on upcoming changes related to both the meeting of the UN in the summer of 2015 and the cannabis regulations being considered for the 2016 election cycle.
1.0 general CEUs approved by OBNM - The Endocannabinoid system: CB Activating Plant Molecules Beyond CannabisPresenter: Kevin Spelman, PhDOriginal Date: July 11, 2015
The endogenous cannabinoids are ubiquitous in mammalian physiology and affect many tissues and pathways including immune function, metabolism and neurological tone. Echinacea alkylamides have been noted to bind the CB2 receptor, but there are other phytochemicals known to interface with the endocannabinoid system that are little known and yet commonly consumed. We will review the role of the endocannabinoid system and discuss various medicinal plant species that impact these common pathways.
1.5 pharmacy CEUs approved by OBNM - High Times: The Pathophysiology of THC Intoxication
Presenter: Laura Ryan, MD, ABMTOriginal Date: July 11, 2015
This presentation will cover the pathophysiology of THC intoxication, as well as methods of use and cultivation. Dr. Ryan will discuss the distribution of cannabinoid receptors in the brain, signs of acute intoxication, the variance between medical and recreational use and treatment options for overdose. Protocol for toxicology screens will also be covered.
1.5 CEUs (including 1.25 general and 0.25 pharmacy) approved by OBNM - Understanding Cannabinoid Pharmacology: Bi-phasic and Bell-shaped Dose Responses
Presenter: Michelle Sexton, NDOriginal Date: July 12, 2015
This presentation will cover the biochemical, physiological and pharmacological aspects of the endocannabinoid system, including: THC and CBD action, Cannabis as a functional adaptogenic herb, and clinical applications. Special focus will be made on the endocannabinergeic system.
1.5 CEUs (including 1.0 general and 0.5 pharmacy) approved by OBNM - The Adverse Effects of Chronic Cannabis Use
Presenter: Paul BergnerOriginal Date: July 12, 2015
Cannabis use is associated with both acute and chronic side effects, including a withdrawal syndrome in habituated chronic users which can lead to a cycle of dependence. Recent research demonstrates the significance of dopamine metabolism in addiction, and also possibly in an amotivational syndrome. Accumulating evidence indicates that deficits in cognition and executive function are nearly universal in chronic users, and are more serious in those who begin using cannabis heavily in their teenage years. A set of syndromes in the traditional Chinese system of medicine is also common in chronic users.In this presentation, you will learn to recognize the symptoms of acute cannabis withdrawal as well as the possible contribution of cannabis use to anxiety, insomnia, depression, cognitive or reproductive disorders, or hyperemesis. Bergner also covers the interrelated pharmacology of cannabinoids and dopamine in the presentation of cannabis dependence, withdrawal, and side effects.
2.0 CEUs (including 0.75 pharmacy and 1.25 general) approved by OBNM - CBD: The Anxiolytic, Anti-inflammatory, Anti-cancer, Non-Euphoric Cannabinoid
Presenter: Kevin Spelman, PhD, MCPPOriginal Date: July 12, 2015
Besides THC there are at least 60 other cannabinoids in the Cannabis plant. Currently there is a significant amount of attention being put on cannabidiol (CBD). This cannabinoid does not induce a “high” but does show some intriguing activity in a number of physiological systems and molecular pathways including attenuating the euphoria of THC. In addition, it puts other receptors into play besides the CBs.In this presentation, you will learn how to distinguish between the CB1, CB2 and CB3 receptors as well as identify the method of action of the anti-inflammatory activity of CBD. Dr. Spelman also discusses some pathways of CBD which have anti-cancer activity.
1.5 pharmacy CEUs approved by OBNM
